Gunderson Dettmer client TScan Therapeutics, a company dedicated to unleashing the power of the immune system through life-changing T cell therapies, has announced its Series B financing of $48 million.  Novartis Venture Fund, Novartis Institutes for BioMedical Research (NIBR), Bessemer Venture Partners, GV and founding investor Longwood Fund participated in the round.

In the announcement of the funding TScan CEO David Southwell said, “I am proud that we have assembled an outstanding team of executives along with top-tier investors to drive development of these products internally and to work externally with corporate partners. We are pleased to welcome Novartis Institutes for BioMedical Research to our Series B financing, as they join the strong core of investors from our Series A round of financing.”

The Gunderson Dettmer deal team was led by Tim Ehrlich and included Stephen Damato and George Pothoulakis.